Search

EHA Pediatric Hemato-Oncology Course programme

April 10, 202414:00–17:30: Red Cell and ConsultativeWelcome and presentation of the course.  Aims, expectations, and a brief look back. Presenters and topics
M. de Montalembert: Difficult management problems in sickle cell disease
M. D.

Read more

Practical information

Timelines:Application deadline: September 24, 2024 (15:00 CEST)
Notification of awards: December 2024

When & where do the meetings take place?Workshop 1:
Date: April 22-26, 2025
Venue: Cambridge, UK

CBTH session and EHA Congress:
Date: June 11-15, 2025
Venue: TBC

Workshop 2:
Date:…

Read more

Dates and deadlines

You may find in this page all the dates and deadlines related to the EHA2025 Congress.  All deadlines, except if mentioned differently, end at 23:59 CET/CEST.  

The timelines will be updated regularly.

Read more

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma in the POLLUX Study

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

Adolescents and young adults (AYA)

Spotlight on AYAAdolescents and young adults (AYA) with hematologic diseases are a unique group with special characteristics and needs. In recent years, the challenges related to the management of AYA (particularly in relation to cancer) have increasingly been recognized.

Read more